Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
A129323-10mg | 10mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $251.90 | |
A129323-50mg | 50mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $1,132.90 | |
A129323-250mg | 250mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $5,097.90 | |
A129323-1g | 1g | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $18,352.90 | |
A129323-5g | 5g | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $82,586.90 |
Potent, irreversible Her2/ErbB 2 and EGFR kinase inhibitor
Synonyms | Afatinib|439081-18-2|850140-72-6|Tovok|BIBW2992|Tomtovok|BIBW 2992|BIBW-2992|Afatinib (BIBW2992)|(S,E)-N-(4-((3-Chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide|Afatinib, Free Base|afatinibum|BIBW29 |
---|---|
Specifications & Purity | 95% |
Storage Temp | Store at -20°C |
Shipped In | Dry ice |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
IUPAC Name | (E)-N-[4-(3-chloro-4-fluoroanilino)-7-[(3S)-oxolan-3-yl]oxyquinazolin-6-yl]-4-(dimethylamino)but-2-enamide |
---|---|
INCHI | InChI=1S/C24H25ClFN5O3/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15/h3-6,10-12,14,16H,7-9,13H2,1-2H3,(H,30,32)(H,27,28,29)/b4-3+/t16-/m0/s1 |
InChi Key | ULXXDDBFHOBEHA-CWDCEQMOSA-N |
Canonical SMILES | CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4 |
Isomeric SMILES | CN(C)C/C=C/C(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)O[C@H]4CCOC4 |
PubChem CID | 10184653 |
Molecular Weight | 485.94 |
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
Certificate of Analysis | Feb 04, 2023 | A129323 | |
Certificate of Analysis | Feb 04, 2023 | A129323 | |
Certificate of Analysis | Feb 04, 2023 | A129323 | |
Certificate of Analysis | Feb 04, 2023 | A129323 | |
Certificate of Analysis | Feb 04, 2023 | A129323 |
Solubility | DMSO 97 mg/mL Water <1 mg/mL Ethanol 15 mg/mL |
---|
Pictogram(s) | GHS06,GHS08,GHS09,GHS07 |
---|---|
Signal | Danger |
Hazard Statements | H319,H301,H410,H372,H361,H362 |
Precautionary Statements | P305+P351+P338,P273,P280,P321,P405,P501,P264,P260,P270,P391,P330,P263,P203,P264+P265,P301+P316,P318,P337+P317,P319 |
1. Shen CH et al.. (2021) ZNRF1 Mediates Epidermal Growth Factor Receptor Ubiquitination to Control Receptor Lysosomal Trafficking and Degradation.. Front Cell Dev Biol, 9 (642625). [PMID:33996800] |